Giuseppina Daniela Naimo

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Adiponectin increases LKB1 expression in ERα-positive breast cancer cells Adiponectin exerts its effects through the activation of its canonical signaling pathway LKB1/AMPK/mTOR.26 It is worth to remark that LKB1, acting as ERα coactivator, promotes proliferation in adiponectin-treated breast cancer cells.4 Here, we demonstrated that adiponectin was able to upregulate LKB1 mRNA and protein contents only in ERα-positive cells (MCF-7 and ZR-75-1) in a dose-related manner (Figures 2A,B and ).

3. Breast Cancer and Obesity Breast cancer consists of a heterogeneous group of malignant tumors that are different in morphology, gene expression patterns, tumor behavior, clinical management, and prognosis [72]. The traditional, histological, pathological staging and tumor differentiation classifications provide diagnostic and prognostic information that is still important but not sufficient to satisfy the need for personalized therapies [72].